Waisman Clinical BioManufacturing Facility to produce pre-flu vaccine

CytoDyn, Inc. has selected the Waisman Clinical BioManufacturing Facility at the University of Wisconsin at Madison to manufacture the Company’s DNA-based pre-flu vaccine. CytoDyn’s pre-flu vaccine provides an alternative approach to immunization that could make flu vaccines for the seasonal flu and bird flu more effective. It uses DNA technology to implant a false memory of previous exposure to the flu virus, including the inactivated virus contained in standard vaccines.

Located at the University of Wisconsin-Madison’s Waisman Center, the Waisman Clinical BioManufacturing Facility (WCBF) is designed to manufacture clinical-grade biological pharmaceuticals for Phase I and II human clinical trials. In addition to facilities and equipment for producing plasmid DNA, WCBF has facilities for processing cell therapeutics, aseptic filling of parenteral therapeutics, and for producing recombinant proteins expressed in bacterial or mammalian systems. WCBF is also capable of providing services such as process development, analytical methods development, analysis of biologics, and quality assurance. With its broad and comprehensive capabilities, WCBF can provide assistance to investigators and companies throughout the entire process of developing a manufacturing process, including production and testing materials for human clinical trials.